Search Results - "Jardine, Meg J"

Burden of Care and Quality of Life Among Caregivers for Adults Receiving Maintenance Dialysis: A Systematic Review by Gilbertson, Elise L., Krishnasamy, Rathika, Foote, Celine, Kennard, Alice L., Jardine, Meg J., Gray, Nicholas A.

“…Dialysis is a burdensome and complex treatment for which many recipients require support from caregivers. The impact of caring for people dependent on dialysis…”
Get full text

Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis by Arnott, Clare, Li, Qiang, Kang, Amy, Neuen, Brendon L, Bompoint, Severine, Lam, Carolyn S P, Rodgers, Anthony, Mahaffey, Kenneth W, Cannon, Christopher P, Perkovic, Vlado, Jardine, Meg J, Neal, Bruce

“…Background Several trials have demonstrated protective effects from inhibition of sodium-glucose cotransporter 2 among patients with type 2 diabetes mellitus…”
Get full text

Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial by Jardine, Meg J, Zhou, Zien, Mahaffey, Kenneth W, Oshima, Megumi, Agarwal, Rajiv, Bakris, George, Bajaj, Harpreet S, Bull, Scott, Cannon, Christopher P, Charytan, David M, de Zeeuw, Dick, Di Tanna, Gian Luca, Greene, Tom, Heerspink, Hiddo J L, Levin, Adeera, Neal, Bruce, Pollock, Carol, Qiu, Rose, Sun, Tao, Wheeler, David C, Zhang, Hong, Zinman, Bernard, Rosenthal, Norman, Perkovic, Vlado

“…Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by…”
Get full text

Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study by Jun, Min, Jardine, Meg J, Perkovic, Vlado, Pilard, Quentin, Billot, Laurent, Rodgers, Anthony, Rogers, Kris, Gallagher, Martin

“…Data on hyperkalemia frequency among chronic kidney disease (CKD) patients receiving renin-angiotensin aldosterone system inhibitors (RAASis) and its impact on…”
Get full text

Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial by Heerspink, Hiddo J.L., Oshima, Megumi, Zhang, Hong, Li, Jingwei, Agarwal, Rajiv, Capuano, George, Charytan, David M., Craig, Jagriti, de Zeeuw, Dick, Di Tanna, Gian Luca, Levin, Adeera, Neal, Bruce, Perkovic, Vlado, Wheeler, David C., Yavin, Yshai, Jardine, Meg J.

“…Canagliflozin reduced the risk of kidney failure and related outcomes in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) in the…”
Get full text

Forgotten Technology in the COVID-19 Pandemic: Filtration Properties of Cloth and Cloth Masks—A Narrative Review by Clase, Catherine M., Fu, Edouard L., Ashur, Aurneen, Beale, Rupert C.L., Clase, Imogen A., Dolovich, Myrna B., Jardine, Meg J., Joseph, Meera, Kansiime, Grace, Mann, Johannes F.E., Pecoits-Filho, Roberto, Winkelmayer, Wolfgang C., Carrero, Juan J.

“…Management of the global crisis of the coronavirus disease 2019 pandemic requires detailed appraisal of evidence to support clear, actionable, and consistent…”
Get full text

The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial by Arnott, Clare, Huang, Yuli, Neuen, Brendon L, Di Tanna, Gian Luca, Cannon, Christopher P., Oh, Richard, Edwards, Robert, Kavalam, Mary, Rosenthal, Norman, Perkovic, Vlado, Jardine, Meg J, Mahaffey, Kenneth, Neal, Bruce

“…Aim To determine whether there was an explanation as to why the effects of the sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor canagliflozin on amputation…”
Get full text

A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device Study by Krishnasamy, Rathika, Hawley, Carmel M, Jardine, Meg J, Roberts, Matthew A, Cho, Yeoungjee, Wong, Muhgeot, Heath, Anne, Nelson, Craig L, Sen, Shaundeep, Mount, Peter F, Pascoe, Elaine M, Vergara, Liza A, Paul-Brent, Peta-Anne, Toussaint, Nigel D, Johnson, David W, Hutchison, Colin A

“…A new class of dialysis membrane, the mid cut-off (MCO) dialyzer, has been developed to improve the clearance of uremic toxins in hemodialysis (HD). The a…”
Get more information

Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials by Heerspink, Hiddo J Lambers, PharmD, Ninomiya, Toshiharu, MD, Zoungas, Sophia, MD, de Zeeuw, Dick, Prof, Grobbee, Diederick E, Prof, Jardine, Meg J, MD, Gallagher, Martin, MD, Roberts, Matthew A, MD, Cass, Alan, Prof, Neal, Bruce, Prof, Perkovic, Vlado, Dr

“…Summary Background Patients undergoing dialysis have a substantially increased risk of cardiovascular mortality and morbidity. Although several trials have…”
Get full text

Buttonhole Cannulation and Clinical Outcomes in a Home Hemodialysis Cohort and Systematic Review by Muir, Christopher A, Kotwal, Sradha S, Hawley, Carmel M, Polkinghorne, Kevan, Gallagher, Martin P, Snelling, Paul, Jardine, Meg J

“…The relative merits of buttonhole (or blunt needle) versus rope ladder (or sharp needle) cannulation for hemodialysis vascular access are unclear. Clinical…”
Get full text

Effects of Fibrates in Kidney Disease by Jun, Min, BSc(Hons), MSc(ClinEpi), Zhu, Bin, MD, PhD, Tonelli, Marcello, MD, PhD, Jardine, Meg J., MBBS, PhD, Patel, Anushka, MBBS, PhD, Neal, Bruce, MB, ChB, PhD, Liyanage, Thaminda, MBBS, Keech, Anthony, MBBS, MSc (Epid), Cass, Alan, MBBS, PhD, Perkovic, Vlado, MBBS, PhD

“…Objectives The purpose of this systematic review and meta-analysis was to determine the efficacy and safety of fibrate therapy in the chronic kidney disease…”
Get full text

Effect of Hemodiafiltration or Hemofiltration Compared With Hemodialysis on Mortality and Cardiovascular Disease in Chronic Kidney Failure: A Systematic Review and Meta-analysis of Randomized Trials by Wang, Amanda Y., MBBS, FRACP, Ninomiya, Toshiharu, MD, PhD, Al-Kahwa, Anas, BSc(Med), Perkovic, Vlado, MBBS, PhD, FRACP, Gallagher, Martin P., MBBS, PhD, FRACP, Hawley, Carmel, MBBS (Hons), M Med Sci, FRACP, Jardine, Meg J., MBBS, PhD, FRACP

“…Background Whether convective modalities of dialysis, including hemofiltration (HF) and hemodiafiltration (HDF), improve cardiovascular outcomes and mortality…”
Get full text

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial by Wada, Takashi, Mori‐Anai, Kazumi, Kawaguchi, Yutaka, Katsumata, Hideyuki, Tsuda, Hidetaka, Iida, Mitsutaka, Arakawa, Kenji, Jardine, Meg J

“…ABSTRACT Aims/Introduction The sodium–glucose cotransporter 2 inhibitor, canagliflozin, reduced kidney failure and cardiovascular events in the Canagliflozin…”
Get full text

Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial by van der Hoek, Sjoukje, Jongs, Niels, Oshima, Megumi, Neuen, Brendon L, Stevens, Jasper, Perkovic, Vlado, Levin, Adeera, Mahaffey, Kenneth W, Pollock, Carol, Greene, Tom, Wheeler, David C, Jardine, Meg J, Heerspink, Hiddo J L

“…In the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, the sodium-glucose cotransporter-2 (SGLT2)…”
Get full text

The effects of dipeptidyl peptidase‐4 inhibitors on kidney outcomes by O'Hara, Daniel V., Parkhill, Thomas R., Badve, Sunil V., Jun, Min, Jardine, Meg J., Perkovic, Vlado

“…Aims To summarize evidence from randomized controlled trials (RCTs) concerning the effects of dipeptidyl peptidase‐4 (DPP‐4) inhibitors on kidney outcomes in…”
Get full text

How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents? by Sukkar, Louisa, Young, Tamara, Jardine, Meg J.

“…Background: Type 2 diabetes mellitus (T2DM) is frequently associated with the development of cardiovascular disease and chronic kidney disease (CKD). Some…”
Get full text

The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials by Kang, Amy, Smyth, Brendan, Neuen, Brendon L., Heerspink, Hiddo J. L., Di Tanna, Gian Luca, Zhang, Hong, Arnott, Clare, Hockham, Carinna, Agarwal, Rajiv, Bakris, George, Charytan, David M., Zeeuw, Dick, Greene, Tom, Levin, Adeera, Pollock, Carol, Wheeler, David C., Mahaffey, Kenneth W., Perkovic, Vlado, Jardine, Meg J.

“…Aims To assess whether the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin affects risk of non‐genital skin and soft tissue infections (SSTIs)…”
Get full text

Prediction of Kidney-Related Outcomes in Patients With Type 2 Diabetes by Jardine, Meg J., MBBS, PhD, Hata, Jun, MD, PhD, Woodward, Mark, PhD, Perkovic, Vlado, MBBS, PhD, Ninomiya, Toshiharu, MD, PhD, Arima, Hisatomi, MD, PhD, Zoungas, Sophia, MBBS, PhD, Cass, Alan, MBBS, PhD, Patel, Anushka, MBBS, PhD, Marre, Michel, MD, PhD, Mancia, Giuseppe, MD, PhD, Mogensen, Carl E., MD, Poulter, Neil, MD, Chalmers, John, MD, PhD

“…Background Tools are needed to predict which individuals with diabetes will develop kidney disease and its complications. Study Design An observational…”
Get full text

Scoring Risk Scores: Considerations Before Incorporating Clinical Risk Prediction Tools Into Your Practice by Foote, Celine, MD, PhD, Woodward, Mark, PhD, Jardine, Meg J., MD, PhD

Get full text

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials by Fletcher, Robert A, Arnott, Clare, Rockenschaub, Patrick, Schutte, Aletta E, Carpenter, Lewis, Vaduganathan, Muthiah, Agarwal, Rajiv, Bakris, George, Chang, Tara I, Heerspink, Hiddo J L, Jardine, Meg J, Mahaffey, Kenneth W, Neal, Bruce, Pollock, Carol, Jun, Min, Rodgers, Anthony, Perkovic, Vlado, Neuen, Brendon L

“…Background Sodium glucose cotransporter-2 inhibitors reduce systolic blood pressure (SBP), but whether they affect SBP variability is unknown. There also…”
Get full text